Suppr超能文献

糖基化在脂蛋白代谢中的作用新见解。

New insights into the role of glycosylation in lipoprotein metabolism.

机构信息

aDepartment of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands bDepartments of Genetics and Medicine, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.

出版信息

Curr Opin Lipidol. 2017 Dec;28(6):502-506. doi: 10.1097/MOL.0000000000000461.

Abstract

PURPOSE OF REVIEW

Human genetics has provided new insights into the role of protein glycosylation in regulating lipoprotein metabolism. Here we review these new developments and discuss the biological insights they provide.

RECENT FINDINGS

Case descriptions of patients with congenital defects in N-glycosylation (CDG-I) frequently describe a distinct hypocholesterolemia in these rare multisystem clinical syndromes. Two novel CDGs with disturbed Golgi homeostasis and trafficking defects result in mixed glycosylation disorders, hepatic steatosis and hypercholesterolemia. In addition, the presence of particular N-glycans is essential for physiological membrane expression of scavenger receptor B1 and for adequate lipolytic activity of endothelial lipase. GalNAc-T2, a specific O-glycosyl transferase, was found to be a direct modulator of HDL metabolism across mammals, validating its relationship with HDL-c found in genome-wide association studies. Furthermore, genetic variation in ASGR1, the major subunit of the asialoglycoprotein receptor (ASGPR), was found to be associated with a reduction in LDL-c and risk of coronary artery disease.

SUMMARY

Protein glycosylation plays an important regulatory role in lipoprotein metabolism. Greater insight into how protein glycosylation regulates lipoprotein metabolism could provide novel approaches for the treatment of dyslipidemia.

摘要

目的综述

人类遗传学为蛋白糖基化在调节脂蛋白代谢中的作用提供了新的见解。本文回顾了这些新进展,并讨论了它们提供的生物学见解。

最近的发现

描述先天性 N-糖基化缺陷(CDG-I)患者的病例报告经常描述这些罕见的多系统临床综合征中存在明显的低胆固醇血症。两种新的伴有高尔基体稳态和运输缺陷的 CDG 导致混合糖基化紊乱、肝脂肪变性和高胆固醇血症。此外,特定 N-聚糖的存在对于清道夫受体 B1 的生理膜表达和内皮脂肪酶的充分脂解活性是必需的。GalNAc-T2 是一种特异性 O-糖基转移酶,被发现是跨哺乳动物 HDL 代谢的直接调节剂,验证了其与全基因组关联研究中发现的 HDL-c 的关系。此外,发现作为糖蛋白受体(ASGPR)主要亚基的 ASGR1 中的遗传变异与 LDL-c 降低和冠心病风险相关。

总结

蛋白糖基化在脂蛋白代谢中起着重要的调节作用。深入了解蛋白糖基化如何调节脂蛋白代谢可能为治疗血脂异常提供新的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验